Some of Australia’s largest blue-chip investors have been caught on the wrong side of one of the year’s most crowded trades after piling into CSL as an alternative to holding a big position in ...

CSL is increasing its US manufacturing capacity, joining other pharmaceutical companies in responding to potential future tariffs on imported pharmaceuticals. The company will invest US$1.5 billion in ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

DEI might still be alive and well on the West Coast. The US government has begun shooting down up to 450,000 barred owls across California, Oregon and Washington — in a controversial culling effort to ...

The U.S. Fish and Wildlife Service is preparing to kill nearly half a million barred owls throughout Washington, Oregon and California after a short-lived effort to halt the cull was thwarted in the ...

Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

CSL showcases Seqirus revenue growth and market leadership at its 2025 Capital Markets Day in Chicago. CSL's Seqirus division has grown revenue from $751 million in FY16 to a projected $2 billion in ...

Good morning, ladies and gentlemen. We still have some people registering, but we always start our Board meetings on time at CSL. So today will be no exception. Welcome to CSL's 2025 Annual General ...

SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...